Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 870

2.

Ursodeoxycholic acid after common bile duct stones removal for prevention of recurrence: A systematic review and meta-analysis of randomized controlled trials.

Chen X, Yan XR, Zhang LP.

Medicine (Baltimore). 2018 Nov;97(45):e13086. doi: 10.1097/MD.0000000000013086. Review.

3.

Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of Kasai procedure: A systematic review and meta-analysis.

Qiu JL, Shao MY, Xie WF, Li Y, Yang HD, Niu MM, Xu H.

Medicine (Baltimore). 2018 Aug;97(35):e12005. doi: 10.1097/MD.0000000000012005. Review.

4.

Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.

Fan X, Zhu Y, Men R, Wen M, Shen Y, Lu C, Yang L.

Can J Gastroenterol Hepatol. 2018 Aug 2;2018:1965492. doi: 10.1155/2018/1965492. eCollection 2018.

5.

Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.

Boelle PY, Debray D, Guillot L, Clement A, Corvol H; French CF Modifier Gene Study Investigators.

Hepatology. 2018 Jul 30. doi: 10.1002/hep.30148. [Epub ahead of print]

PMID:
30058245
6.

Ursodiol.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

7.

Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice.

Dorvash MR, Khoshnood MJ, Saber H, Dehghanian A, Mosaddeghi P, Firouzabadi N.

Eur J Pharmacol. 2018 Aug 15;833:165-172. doi: 10.1016/j.ejphar.2018.06.002. Epub 2018 Jun 5.

PMID:
29883669
8.

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.

N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.

PMID:
29874528
9.

Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia.

Bordbar M, Shakibazad N, Fattahi M, Haghpanah S, Honar N.

Turk J Gastroenterol. 2018 Mar;29(2):203-209. doi: 10.5152/tjg.2018.17521.

PMID:
29749328
10.

Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.

Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, Shen H, Yang J, Xiong T, Steggerda J, Liu Z, Noureddin M, Maldonado SS, Annamalai A, Seki E, Mato JM, Lu SC.

Gastroenterology. 2018 Aug;155(2):557-571.e14. doi: 10.1053/j.gastro.2018.04.032. Epub 2018 May 5.

PMID:
29733835
11.

Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.

Nassereddine S, Alsubait S, Tabbara I.

Anticancer Res. 2018 May;38(5):2597-2605. Review.

PMID:
29715079
12.

Glucocorticoids in combination with ursodesoxycholic acid in the treatment of autoimmune hepatitis.

Li WY, Yang XS, Wang YC.

J Biol Regul Homeost Agents. 2018 Mar-Apr;32(2):307-311.

PMID:
29685011
13.

Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.

Kim MJ, Kang YJ, Kwon M, Choi YA, Choi MK, Chi HY, Yoo HH, Shim CK, Song IS.

Int J Mol Sci. 2018 Apr 9;19(4). pii: E1120. doi: 10.3390/ijms19041120.

14.

[Primary biliary cholangitis. Part 1. State of the art, epidemiology, physiopathology and clinical manifestations].

Rodríguez Lugo DA, Coronado Tovar JJ, Solano Villamarin GA, Otero Regino W.

Rev Gastroenterol Peru. 2017 Oct-Dec;37(4):357-364. Review. Spanish.

PMID:
29459807
15.

Hepatotoxicity Associated With Vismodegib.

Bedi PS, Rai MP, Tageja N, Laird-Fick H.

BMJ Case Rep. 2018 Feb 8;2018. pii: bcr-2017-222969. doi: 10.1136/bcr-2017-222969.

PMID:
29437771
16.

Does ursodeoxycholic acid improve perinatal outcomes in women with intrahepatic cholestasis of pregnancy?

Chappell LC, Chambers J, Thornton JG, Williamson C.

BMJ. 2018 Feb 1;360:k104. doi: 10.1136/bmj.k104. No abstract available.

PMID:
29419378
17.

Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice.

Zhang L, Su H, Li Y, Fan Y, Wang Q, Jiang J, Hu Y, Chen G, Tan B, Qiu F.

Toxicol Appl Pharmacol. 2018 Mar 1;342:69-78. doi: 10.1016/j.taap.2018.01.019. Epub 2018 Feb 1.

PMID:
29407775
18.

Cilostazol attenuates indices of liver damage induced by thioacetamide in albino rats through regulating inflammatory cytokines and apoptotic biomarkers.

El Awdan SA, Amin MM, Hassan A.

Eur J Pharmacol. 2018 Mar 5;822:168-176. doi: 10.1016/j.ejphar.2018.01.021.

PMID:
29355562
19.

Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation.

Quigley G, Al Ani M, Nadir A.

Dig Dis Sci. 2018 Feb;63(2):529-532. doi: 10.1007/s10620-017-4900-8. Epub 2018 Jan 5. No abstract available.

PMID:
29305737
20.

Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).

Boerlage TCC, Haal S, Maurits de Brauw L, Acherman YIZ, Bruin S, van de Laar AWJM, Moes DE, van Wagensveld BA, de Vries CEE, van Veen R, Schouten R, Dijkgraaf MG, Fockens P, Gerdes VEA, Voermans RP.

BMC Gastroenterol. 2017 Dec 20;17(1):164. doi: 10.1186/s12876-017-0674-x.

Supplemental Content

Loading ...
Support Center